Information for "Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies"
Basic information
| Display title | Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies |
| Default sort key | Phase I Pharmacogenomic Substance Conversation Research involving Sorafenib and also Bevacizumab together with Paclitaxel throughout People with Advanced Refractory Strong Malignancies |
| Page length (in bytes) | 3,640 |
| Namespace ID | 0 |
| Page ID | 378154 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Disallowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Mittendew6 (talk | contribs) |
| Date of page creation | 10:34, 17 January 2024 |
| Latest editor | Mittendew6 (talk | contribs) |
| Date of latest edit | 10:34, 17 January 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
